ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment Phase 1 trial results expected in the first half of 2025 SOLANA BEACH, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today ...

Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that George Warren, Ph.D., Principal Scientist ...

Core Insights - Artelo Biosciences, Inc. is advancing its clinical-stage pharmaceutical development focused on lipid-signaling pathways to treat cancer, pain, and other conditions [1][6] - The company presented preclinical data on ART26.12, a novel fatty acid binding protein 5 (FABP5) inhibitor, at the 34th Annual International Cannabinoid Research Society Symposium [1][2] Group 1: Product Development - ART26.12 has shown efficacy in reducing pain behaviors associated with breast cancer in preclinical studies, consistent with previous findings in other pain models [2][3] - The drug is being developed as a non-opioid, non-steroidal analgesic treatment, with plans to initiate human trials pending FDA approval [3][4] - ART26.12 targets FABP5, which is overexpressed in various pathologies, and aims to address significant unmet needs in pain management [4][6] Group 2: Market Context - Breast cancer is the most common cancer in women, with over half of advanced cases leading to bone metastasis and associated pain [3] - The International Cannabinoid Research Society (ICRS) serves as a platform for researchers in the cannabinoid field, highlighting the growing interest in cannabinoid-related therapies [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38951 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada (State or ...

SOLANA BEACH, Calif., May 13, 2024 (GLOBE NEWSWIRE) --  Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the three months ended March 31, 2024 and provided a business update. "Our entire clinical and preclinical development portfolio is progressing as planned," commented Gregory D ...

SOLANA BEACH, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that it will be participating in the 2024 Pharma Partnering Summit being held May 14th – 15th in San Diego, California. Gregory D. Gorgas, President and Chief Executive Officer of Artelo, is scheduled to present ...

Core Insights - Artelo Biosciences, Inc. has published an article in Drug Discovery Today discussing the role of fatty acid binding protein 7 (FABP7) in various cancers and its potential as a target for cancer treatment [1][2] - FABP7 is upregulated in several cancers, including breast, brain, and kidney cancers, and is associated with poor patient prognosis [2] - Genetic and pharmacological inhibition of FABP7 has shown to reduce tumor cell growth, migration, and invasion, while improving survival rates in brain cancer models [2] Company Developments - Artelo is advancing research on FABP inhibition, focusing on selective and pan-FABP inhibitors to provide new therapeutic options for cancer and other serious conditions [3] - The lead compound, ART26.12, is a selective inhibitor of FABP5, showing positive preclinical results in cancer and chemotherapy-induced peripheral neuropathy (CIPN) [3][5] - The company plans to file an investigational new drug (IND) application with the FDA for ART26.12 in CIPN during Q2 2024, addressing a significant unmet need as approximately 40% of cancer patients undergoing certain chemotherapies develop neuropathic pain [3][5] Research Focus - Artelo's research emphasizes the therapeutic potential of its extensive library of small molecule FABP inhibitors for treating various conditions, including cancers, pain, and anxiety disorders [5][6] - The company is dedicated to developing proprietary therapeutics that modulate lipid-signaling pathways to address significant unmet medical needs [6]

SOLANA BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that Gregory D. Gorgas, President and Chief Executive Officer of Artelo, will be a featured guest on the Benzinga All Access show. Mr. Gorgas is scheduled to appear on Tuesday, April 23, 2024, at approximately ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 001-38951 Artelo Biosciences, Inc. (Exact name of registrant as specified in its charter) | --- | |------------ ...

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson's (("J&amp, J's", NYSE:JNJ) Innovation Challenge. This invitation-only event seeks novel approaches to treating atopic dermatitis from around the world. Artelo was awarded th ...